NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. NervGen Pharma Corp. is based in VANCOUVER, British Columbia.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-31.58M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 33.54 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -3272.64% |
| Return on Assets (Trailing 12 Months) | -228.15% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.34 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.09 |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 80.63M |
| Free Float | 75.95M |
| Market Capitalization | $135.46M |
| Average Volume (Last 20 Days) | 0.66M |
| Beta (Past 60 Months) | -- |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.80% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |